Bioceltix S.A.
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more
Market Cap & Net Worth: Bioceltix S.A. (BCX)
Bioceltix S.A. (WAR:BCX) has a market capitalization of $91.67 Million (zł381.15 Million) as of March 18, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #19635 globally and #101 in its home market, demonstrating a -0.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioceltix S.A.'s stock price zł77.40 by its total outstanding shares 4924468 (4.92 Million).
Bioceltix S.A. Market Cap History: 2021 to 2026
Bioceltix S.A.'s market capitalization history from 2021 to 2026. Data shows growth from $61.82 Million to $91.67 Million (19.98% CAGR).
Bioceltix S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioceltix S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BCX by Market Capitalization
Companies near Bioceltix S.A. in the global market cap rankings as of March 18, 2026.
Key companies related to Bioceltix S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Bioceltix S.A. Historical Marketcap From 2021 to 2026
Between 2021 and today, Bioceltix S.A.'s market cap moved from $61.82 Million to $ 91.67 Million, with a yearly change of 19.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł91.67 Million | -0.26% |
| 2025 | zł91.90 Million | -11.42% |
| 2024 | zł103.75 Million | -2.67% |
| 2023 | zł106.59 Million | +131.96% |
| 2022 | zł45.95 Million | -25.67% |
| 2021 | zł61.82 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bioceltix S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $91.67 Million USD |
| MoneyControl | $91.67 Million USD |
| MarketWatch | $91.67 Million USD |
| marketcap.company | $91.67 Million USD |
| Reuters | $91.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.